

Policy: MP055

Section: Medical Benefit Policy

Subject: Mastectomy for Gynecomastia

Applicable Lines of Business

Commercial	X	CHIP	X
Medicare	X	ACA	X
Medicaid	X		

I. Policy: Mastectomy for Gynecomastia

II. Purpose/Objective:

To provide a policy of coverage regarding Mastectomy for Gynecomastia

III. Responsibility:

- A. Medical Directors
- B. Medical Management

IV. Required Definitions

1. Attachment – a supporting document that is developed and maintained by the policy writer or department requiring/authoring the policy.
2. Exhibit – a supporting document developed and maintained in a department other than the department requiring/authoring the policy.
3. Devised – the date the policy was implemented.
4. Revised – the date of every revision to the policy, including typographical and grammatical changes.
5. Reviewed – the date documenting the annual review if the policy has no revisions necessary.

Commercial

Geisinger Health Plan may refer collectively to health care coverage sponsors Geisinger Health Plan, Geisinger Quality Options, Inc., and Geisinger Indemnity Insurance Company, unless otherwise noted. Geisinger Health Plan is part of Geisinger, an integrated health care delivery and coverage organization.

Medicare

Geisinger Gold Medicare Advantage HMO, PPO, and HMO D-SNP plans are offered by Geisinger Health Plan/Geisinger Indemnity Insurance Company, health plans with a Medicare contract. Continued enrollment in Geisinger Gold depends on contract renewal. Geisinger Health Plan/Geisinger Indemnity Insurance Company are part of Geisinger, an integrated health care delivery and coverage organization.

CHIP

Geisinger Health Plan Kids (GHP Kids) is a Children's Health Insurance Program (CHIP) offered by Geisinger Health Plan in conjunction with the Pennsylvania Department of Human Services (DHS). Geisinger Health Plan is part of Geisinger, an integrated health care delivery and coverage organization.

Medicaid

Geisinger Health Plan Family (GHP Family) is a Medical Assistance (Medicaid) insurance program offered by Geisinger Health Plan in conjunction with the Pennsylvania Department of Human Services (DHS). Geisinger Health Plan is part of Geisinger, an integrated health care delivery and coverage organization.

V. Additional Definitions

Medical Necessity or Medically Necessary means Covered Services rendered by a Health Care Provider that the Plan determines are:

- a. appropriate for the symptoms and diagnosis or treatment of the Member's condition, illness, disease or injury;
- b. provided for the diagnosis, and the direct care and treatment of the Member's condition, illness disease or injury;
- c. in accordance with current standards of good medical treatment practiced by the general medical community.
- d. not primarily for the convenience of the Member, or the Member's Health Care Provider; and
- e. the most appropriate source or level of service that can safely be provided to the Member. When applied to hospitalization, this further means that the Member requires acute care as an inpatient due to the nature of the services rendered or the Member's condition, and the Member cannot receive safe or adequate care as an outpatient.

Medicaid Business Segment

Medically Necessary — A service, item, procedure, or level of care that is necessary for the proper treatment or management of an illness, injury, or disability is one that:

- Will, or is reasonably expected to, prevent the onset of an illness, condition, injury or disability.
- Will, or is reasonably expected to, reduce or ameliorate the physical, mental or developmental effects of an illness, condition, injury or disability.
- Will assist the Member to achieve or maintain maximum functional capacity in performing daily activities, taking into account both the functional capacity of the Member and those functional capacities that are appropriate for Members of the same age

Gynecomastia - The American Society of Plastic Surgeons (ASPS) defines gynecomastia as:

- Grade I Small breast enlargement with localized button of tissue that is concentrated around the areola.
- Grade II Moderate breast enlargement exceeding areola boundaries with edges that are indistinct from the chest.
- Grade III Moderate breast enlargement exceeding areola boundaries with edges that are distinct from the chest with skin redundancy present.
- Grade IV Marked breast enlargement with skin redundancy and feminization of the breast.

REQUIRES PRIOR AUTHORIZATION BY A PLAN MEDICAL DIRECTOR or Designee:

Commercial and Medicaid Business Segment:

For those product lines in which surgical treatment of gynecomastia is not specifically excluded, the following criteria will be used to determine eligibility for coverage. All must be met:

- Member is of age 18 years or older or puberty is substantially completed; and
- Gynecomastia meets ASPS Grade II, III, or IV definition (see Definitions Section); and
- Condition is present for no less than 2 years and contributing factors have been treated for at least 6 months; and
- Excess breast tissue is glandular and not fatty, confirmed by mammogram and/or tissue histology; and
- Other causes including obesity (BMI greater than or equal to 35) or reversible drug therapy have been ruled out; and
- The member must be excluded from, or failed treatment of, an underlying hormone disorder; and
- Excessive breast development is not due to non-covered therapies or illicit drug use

Mastectomy for gynecomastia is considered medically necessary, regardless of age, when there is a clinically concern that a breast mass may represent breast carcinoma.

LIMITATIONS:

Medicare Business Segment: Payment may be made for mastectomy for gynecomastia if it is documented that the tissue is primarily breast tissue and not adipose (fatty) tissue. However, if the tissue removed is primarily fatty tissue, the surgery is classified as cosmetic and is not eligible for payment per the current Centers for Medicare Services (CMS) guidelines.

TPA: Individual benefits may vary by employer as outlined in the applicable benefit documents.

EXCLUSIONS:

Mastectomy or liposuction to correct gynecomastia when **NOT COVERED** per the **Exclusions Section**, of the contract specific applicable benefit document.

Medicaid Business Segment:

Any requests for services, that do not meet criteria set in the PARP, may be evaluated on a case by case basis.

Note: A complete description of the process by which a given technology or service is evaluated and determined to be experimental, investigational or unproven is outlined in MP 15 - Experimental Investigational or Unproven Services or Treatment.

CODING ASSOCIATED WITH: Mastectomy for gynecomastia

The following codes are included below for informational purposes and may not be all inclusive. Inclusion of a procedure or device code(s) does not constitute or imply coverage nor does it imply or guarantee provider reimbursement. Coverage is determined by the member specific benefit plan document and any applicable laws regarding coverage of specific services. Please note that per Medicare coverage rules, only specific CPT/HCPCS Codes may be covered for the Medicare Business Segment. Please consult the CMS website at www.cms.gov or the local Medicare Administrative Carrier (MAC) for more information on Medicare coverage and coding requirements

19300 Mastectomy for gynecomastia

Current Procedural Terminology (CPT®) © American Medical Association: Chicago, IL

LINE OF BUSINESS:

Eligibility and contract specific benefit limitations and/or exclusions will apply. Coverage statements found in the line of business specific benefit document will supercede this policy. For Medicare, applicable LCD's and NCD's will supercede this policy. For PA Medicaid Business segment, this policy applies as written.

REFERENCES:

Braunstein, GD, "Current Concepts: Gynecomastia, *The New England Journal of Medicine*, 328(7):490-495, 18 Feb 1993.

Vetto J, Schmidt W, Pommier R, DiTomasso J, Eppich H, Wood W, Moseson D, "Accurate and Cost-effective Evaluation of Breast Masses in Males", *The American Journal of Surgery*, 175(5):383-387, May 1998.

Bowers SP, Pearlman NW, McIntyre RC, Finlayson CA, Huerd S, "Cost-Effective Management of Gynecomastia", *The American Journal of Surgery*, 176(6):638-641, Dec 1998.

Colombo-Benkmann M, Buse B, Stern J, Herfarth C, "Indications For and Results of Surgical Therapy for Male Gynecomastia", *The American Journal of Surgery*, 178(1):60-63, July 1999.

American Society of plastic Surgeons. ASPS Recommended Insurance Coverage Criteria for Third-Party Payers. http://www.plasticsurgery.org/Documents/medical-professionals/health_policy/insurance/Gynecomastia-Insurance-Coverage.pdf

Ladizinski B, Lee KC, Nutan FN, et al. Gynecomastia: etiologies, clinical presentations, diagnosis, and management. *South Med J*. 2014; 107(1):44-49

Fischer S, Hirsch T, Hirche C, et al. Surgical treatment of primary gynecomastia in children and adolescents. *Pediatr Surg Int*. 2014; 30(6):641-647

Rohrich RJ, Ha RY, Kenkel JM, et al. Classification and management of gynecomastia: defining the role of ultrasound-assisted liposuction. *Plast Reconstr Surg*. 2003; 111(2):909-923

Zavlin D, Jubbal KT, Friedman JD, Echo A. Complications and Outcomes After Gynecomastia Surgery: Analysis of 204 Pediatric and 1583 Adult Cases from a National Multi-center Database. *Aesthetic Plast Surg*. 2017; 41(4):761-767.

Choi BS, Lee SR, Byun GY, et al. The Characteristics and Short-Term Surgical Outcomes of Adolescent Gynecomastia. *Aesthetic Plast Surg*. 2017 Apr 27.

Kanakis GA, Nordkap L, Bank AK, et al. EAA clinical practice guidelines-gynecomastia evaluation and management. *Andrology*. 2019; 7(6): 778-793.

Holzmer SW, Lewis PG, Landau MJ, Hill ME. Surgical Management of Gynecomastia: A Comprehensive Review of the Literature. *Plast Reconstr Surg Glob Open*. 2020 Oct 29;8(10):e3161.

Trinchieri A, Perletti G, Magri V, et al. Drug-induced gynecomastia: a systematic review and meta-analysis of randomized clinical trials. *Arch Ital Urol Androl*. 2021 Dec 21;93(4):489-496.

Innocenti A, Melita D, Dreassi E. Incidence of complications for different approaches in gynecomastia correction: a systematic review of the literature. *Aesthetic Plast Surg*. 2022 Jun;46(3):1025-1041.

Prasetyono TOH, Andromeda I, Budhipramono AG. Approach to gynecomastia and pseudogynecomastia surgical techniques and its outcome: a systematic review. *J Plast Reconstr Aesthet Surg*. 2022 May;75(5):1704-1728.

Szar M, Dendy CB, Hillenbrand K. Breast Conditions (Disorders) in Children. *Pediatr Rev*. 2023; 44(11):665-667

Yang X, Zheng X, Zhang M, et al. Drug-induced gynecomastia: data mining and analysis of the FDA adverse event reporting system database. *Clin Epidemiol*. 2024; 16:617-630.

This policy will be revised as necessary and reviewed no less than annually.

Devised: 3/20/98

Revised: 10/99, 03/02, 7/03 (sub-cert reference), 8/04; 8/05 (revised Exclusions); 8/06: 8/08 (wording), 7/16 (Gender Language); 11/16; 11/17 (clarify criteria)

Reviewed: 03/03; 8/07; 8/09; 6/10, 6/11, 6/12, 6/13, 6/14, 11/15, 11/18, 11/19, 11/20, 11/21, 11/22, 11/23, 11/24, 11/25

CMS UM Oversight Committee Approval: 12/23, 12/24, 2/26

Geisinger Health Plan may refer collectively to health care coverage sponsors Geisinger Health Plan, Geisinger Quality Options, Inc., and Geisinger Indemnity Insurance Company, unless otherwise noted. Geisinger Health Plan is part of Geisinger, an integrated health care delivery and coverage organization.

Coverage for experimental or investigational treatments, services and procedures is specifically excluded under the member's certificate with Geisinger Health Plan. Unproven services outside of an approved clinical trial are also specifically excluded under the member's certificate with Geisinger Health Plan. This policy does not expand coverage to services or items specifically excluded from coverage in the member's certificate with Geisinger Health Plan. Additional information can be found in MP015 Experimental, Investigational or Unproven Services.

Prior authorization and/or pre-certification requirements for services or items may apply. Pre-certification lists may be found in the member's contract specific benefit document. Prior authorization requirements can be found at <https://www.geisinger.org/health-plan/providers/ghp-clinical-policies>

Please be advised that the use of the logos, service marks or names of Geisinger Health Plan, Geisinger Quality Options, Inc. and Geisinger Indemnity Insurance Company on a marketing, press releases or any communication piece regarding the contents of this medical policy is strictly prohibited without the prior written consent of Geisinger Health Plan. Additionally, the above medical policy does not confer any endorsement by Geisinger Health Plan, Geisinger Quality Options, Inc. and Geisinger Indemnity Insurance Company regarding the medical service, medical device or medical lab test described under this medical policy.